
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
This guideline topline summary of recommendations for treating hypertension in adults is adapted from the American Academy of Family Physicians clinical guideline.






